Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Colorcon
Dow
McKinsey
Johnson and Johnson

Last Updated: January 27, 2023

Investigational Drug Information for Bococizumab


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Bococizumab?

Bococizumab is an investigational drug.

There have been 10 clinical trials for Bococizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Hyperlipoproteinemias, Hyperlipidemias, and Dyslipidemias. The leading clinical trial sponsors are Pfizer, University of California, San Francisco, and San Francisco General Hospital.

There are seven US patents protecting this investigational drug and eighty-seven international patents.

Recent Clinical Trials for Bococizumab
TitleSponsorPhase
Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia SubjectsPfizerPhase 3
Bococizumab HIV Evaluation (B-HIVE) StudyPfizerPhase 3
Bococizumab HIV Evaluation (B-HIVE) StudySan Francisco General HospitalPhase 3

See all Bococizumab clinical trials

Clinical Trial Summary for Bococizumab

Top disease conditions for Bococizumab
Top clinical trial sponsors for Bococizumab

See all Bococizumab clinical trials

US Patents for Bococizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Bococizumab See Plans and Pricing Peptide-mediated delivery of immunoglobulins across the blood-brain barrier Mayo Foundation for Medical Education and Research (Rochester, MN) See Plans and Pricing
Bococizumab See Plans and Pricing Antigen-binding proteins that activate the leptin receptor REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY) See Plans and Pricing
Bococizumab See Plans and Pricing Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY) See Plans and Pricing
Bococizumab See Plans and Pricing Treatment with anti-PCSK9 antibodies Pfizer Inc. (New York, NY) See Plans and Pricing
Bococizumab See Plans and Pricing Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Bococizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Bococizumab Argentina AR106319 2035-10-12 See Plans and Pricing
Bococizumab Argentina AR115992 2035-10-12 See Plans and Pricing
Bococizumab Australia AU2016338851 2035-10-12 See Plans and Pricing
Bococizumab Brazil BR112018007318 2035-10-12 See Plans and Pricing
Bococizumab Canada CA3000215 2035-10-12 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Colorcon
Dow
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.